As a result, guidelines recommend SGLT-2is as the first-line agent for type 2 diabetes (T2D) patients with established chronic kidney disease (CKD), defined as a sustained reduction in eGFR < 60 mL/min or urine albumin creatinine ratio (UACR) ≥ 200 mg/g [3]. Here, ALB is linked to chronic kidney disease.